Literature DB >> 31296541

Calming the storm in HLH.

Matt S Zinter1, Michelle L Hermiston1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31296541     DOI： 10.1182/blood.2019001333

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Ruxolitinib in conjunction with the HLH-94 protocol for Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in the intensive care unit: A case report.

Authors:  Zoufang Huang; Jiangbo Xie
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

Review 2.  COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.

Authors:  H C Hasselbalch; V Skov; L Kjær; C Ellervik; A Poulsen; T D Poulsen; C H Nielsen
Journal:  Cytokine Growth Factor Rev       Date:  2021-04-14       Impact factor: 7.638

Review 3.  Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities.

Authors:  Puja Mehta; Joanna C Porter; Jessica J Manson; John D Isaacs; Peter J M Openshaw; Iain B McInnes; Charlotte Summers; Rachel C Chambers
Journal:  Lancet Respir Med       Date:  2020-06-16       Impact factor: 30.700

4.  Anakinra for the treatment of adult secondary HLH: a retrospective experience.

Authors:  Leonard Naymagon
Journal:  Int J Hematol       Date:  2022-08-10       Impact factor: 2.319

5.  Systemic autoimmune abnormalities complicated by cytomegalovirus-induced hemophagocytic lymphohistiocytosis: A case report.

Authors:  Shu-Xian Miao; Zhi-Qi Wu; Hua-Guo Xu
Journal:  World J Clin Cases       Date:  2020-10-26       Impact factor: 1.337
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.